SGLT2 inhibitors have revolutionized the management of chronic kidney disease (CKD) by shifting treatment paradigms beyond traditional glucose control. Initially developed as antidiabetic agents, these drugs now offer significant renal protection and cardiovascular benefits. Their ability to reduce the progression of CKD, regardless of diabetes status, positions SGLT2 inhibitors as a cornerstone in nephrology care, transforming the treatment landscape. Join us in this session with our experts, Dr. Gokul Prasannan and Dr. Jacob George to learn more about the topic.